Sort
48,018 grants matching “immunotherapy”
Tumor-associated neutrophils in human lung cancer
$366,000Evgeniy Eruslanov · University Of Pennsylvania · R01 · FY2016 · CA
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer
$366,000Don Lynn Gibbons · University Of Tx Md Anderson Can Ctr · R37 · FY2020 · CA
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer
$366,000Don Lynn Gibbons · University Of Tx Md Anderson Can Ctr · R37 · FY2018 · CA
Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer
$366,000Chunru Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA
Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer
$366,000Chunru Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Fgl-2 targeted therapy for reversing multi-modality immune suppression
$366,000Shulin Li · University Of Tx Md Anderson Can Ctr · R01 · FY2016 · CA
Role of KMT2D and aberrant enhancers in modulating tumor microenvironment in melanoma
$366,000Kunal Rai · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA
Nano-therapeutics Reprogramming of Immunosuppressive Myeloid Cells Potentiate Radiotherapy for Glioblastoma
$366,000Peng Zhang · Northwestern University At Chicago · R37 · FY2022 · CA
Nano-therapeutics Reprogramming of Immunosuppressive Myeloid Cells Potentiate Radiotherapy for Glioblastoma
$366,000Peng Zhang · Northwestern University At Chicago · R37 · FY2025 · CA
Off-the-shelf engineered NK cells for the treatment of AML
$366,000Katy Rezvani · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA
Tumor-associated neutrophils in human lung cancer
$366,000Evgeniy Eruslanov · University Of Pennsylvania · R01 · FY2017 · CA
The molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinoma
$366,000Jianjun Zhang · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy
$366,000Tito R Mendoza · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA
Role of KMT2D and aberrant enhancers in modulating tumor microenvironment in melanoma
$366,000Kunal Rai · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Development of B-cell-based vaccine for Glioblastoma
$366,000Catalina Lee Chang · Northwestern University At Chicago · R37 · FY2022 · CA
A novel pathway to overcome resistance to immunotherapy in melanoma
$366,000Diana Nora Vaz Saleiro · Northwestern University At Chicago · R01 · FY2024 · CA
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy
$366,000Tito R Mendoza · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · CA
Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer
$366,000Chunru Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · CA
The molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinoma
$366,000Jianjun Zhang · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · CA
Off-the-shelf engineered NK cells for the treatment of AML
$366,000Katy Rezvani · University Of Tx Md Anderson Can Ctr · R01 · FY2017 · CA
The molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinoma
$366,000Jianjun Zhang · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers
$366,000Stephen Philip Schoenberger · La Jolla Institute For Immunology · U01 · FY2020 · DE
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer
$366,000Don Lynn Gibbons · University Of Tx Md Anderson Can Ctr · R37 · FY2022 · CA
The molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinoma
$366,000Jianjun Zhang · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
A novel pathway to overcome resistance to immunotherapy in melanoma
$366,000Diana Nora Vaz Saleiro · Northwestern University At Chicago · R01 · FY2025 · CA